While the market seems to be stabilizing (obviously a relative term in this environment), simply hoping for a continual steady move up is not a sound strategy.

While people can argue buy-and-hold vs. other more active strategies, we believe that the recent volatility has caused enough pain that investors are now paying more attention and searching for more active ideas.

So today, we offer five ideas from our stable of newsletters. Each newsletter has an array of ideas, but we will select five each week as a teaser to all the other great ideas you can get from all the different newsletters we offer.

Action Alerts PLUS: Jim Cramer bought 100 shares of Abbott Laboratories ( ABT) at $45. Cramer said, "Abbott has been weak for the past few days on no new information. The chatter is that portfolio managers are taking profits in health care in general and Abbott specifically because it was the best-performing pharma/med-tech last year. Also, there are concerns about Abbott making an acquisition, soft Humira trends and Xience pricing. Abbott has been masterful at doing deals in the past, that's how it got Humira and Xience in the first place." (Jim Cramer, Action Alerts PLUS, April 3, 2009)

Cramer's Action Alerts PLUS portfolio is actually up 1.27% for 2009, vs. a decline in the S&P 500 of about 13%.

In the most recent Action Alerts PLUS, Jim had several other picks. Click here to check them out.

Biotech Select: Adam Feuerstein sold his position in Celgene ( CELG) at $40.40 in the Biotech Select portfolio. Adam said, "Celgene's first-quarter profit warning, announced Tuesday evening, suggests the company is not growing as quickly as expected. As a result, I don't believe the stock will recover significantly for a long time -- and certainly not to the point where I can eke out any gains from the current portfolio position. The stock is bouncing today after a steep selloff Wednesday, so I will use the opportunity to close out this position." (Adam Feuerstein, Biotech Select, March 29, 2009)

Adam Feuerstein's Biotech Select portfolio was up a whopping 12.09% during the first quarter alone.

Biotech Select had some other solid ideas recently. Click here to check them out.

Insider Insights: Jonathan Moreland added Owens Corning ( OC) at $10.25 in the Insider Insights portfolio. Jonathan said, "A household name like Owens Corning with over a billion-dollar market capitalization would seem to have little in common with tiny Buckeye Technologies ( BKI). But the shares of the two will likely trade in concert higher nonetheless if Mr. Market can just keep the momentum going. Each is also similarly vulnerable from a technical point of view if the rally ends up petering right here.

"Owens Corning makes insulation products as well as roofing, asphalt and other building materials. After nearly being brought down by legacy liabilities due to its old asbestos products, the company emerged from bankruptcy reorganization in late 2006. As with just about every other U.S.-traded stock, Owens Corning's shares capped a long decline with a sharp plunge in early March. Nine insiders reacted by buying up $555,783 worth of OC at an average price of $6.62. That round of purchases has already proven very profitable. Alas for insiders, a pair also bought in February for as much as $8.58 per share, and last November for as much as $15.76 per share." (Jonathan Moreland, Insider Insights, April 3, 2009)

Jonathan Moreland's Insider Insights is one of the best-kept secrets around. Check out his other solid picks here.

Nails on the Numbers: Lenny "Nails" Dykstra started a short-term trade in Intel ( INTC) call options. He said, "Time is running out on my position in Intel, so it's time to up the ante by moving the trade to a longer position. The April $15 calls are set to expire in 15 days and have been trading from 56 cents on the low end up to $1.30 on the high end in the past week. With an average price of $1.40, I'd like to get in low and double down on the position one more time. This will provide a better exit price for a win. Shares of Intel don't need to jump very much for this trade to bring home a big score. Therefore, I will buy an additional 880 contracts of the April $15 calls." (Lenny Dykstra, Nails on the Numbers, April 2, 2009)

Lenny has some other great picks in his latest newsletter - you can check them out here.

Stocks Under $10: Frank Curzio and the Stocks Under $10 team started a position in Euroseas ( ESEA). Curzio said, "After you read this Alert, we will buy 500 shares of Euroseas, a Greece-based company that owns and operates a fleet of five dry bulk vessels, 10 container ships and one multipurpose vessel. We believe the stock has a favorable risk/reward profile for investors over the next 12 to 18 months. Shares were recently trading at $3.75.

"Shipping stocks have been hammered over the past 12 months, mostly due to a major slowdown in economic growth across the world. The Baltic Dry Index (BDI), which provides the daily price of moving raw materials (such as coal, crude oil, steel and building supplies) by sea, has collapsed from a high of 11,793 in May 2008 to below 1500 currently. The past few weeks in particular have seen a sharp downturn in the BDI. Conditions in the shipping sector remain weak, and some stocks in the industry are in danger of breaching debt covenants.

"However, Euroseas is not in this camp. Among the positives for this name are its experienced management team -- which was well ahead of the curve in terms of cost-cutting -- and a very strong balance sheet that will help it weather further downturns. In addition, Euroseas is one of the few dry-bulk names to trade at a discount to net asset value. When looking at a particular stock in an industry that has been badly beaten up, it's important to measure the risk against the reward. Euroseas has one of the lowest cost structures among public shippers and one of the lowest leverage ratios, and management is rather conservative in its assumption that there will be little industry growth in 2010." (Frank Curzio, Stocks Under $10, April 9, 2009)

Curzio has had some other great picks recently; to check them out, please click here.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider BKI and ESEA to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

James Altucher is president of Stockpickr LLC, a wholly owned subsidiary of TheStreet.com and part of its network of Web properties, and a managing partner at Formula Capital, an alternative asset management firm that runs a fund of hedge funds. He is also a weekly columnist for the Financial Times and the author of Trade Like a Hedge Fund, Trade Like Warren Buffett and SuperCa$h. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Altucher appreciates your feedback; click here to send him an email.

TheStreet.com has a revenue-sharing relationship with Trader's Library under which it receives a portion of the revenue from purchases by customers directed there from TheStreet.com.